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Background: Chronic obstructive pu lmonary disease (COPD) aremanaged predominantly 
in primary care. However, key opportunities to optimize treatment are often not realized due 
to unrecognized disease and delayed implementation of appropriate interventions for both 
diagnosed and undiagnosed individuals. The COllaboratioN on QUality improvement initia-
tive for achieving Excellence in STandards of COPD care (CONQUEST) is the first-of-its- 
kind, collaborative, interventional COPD registry. It comprises an integrated quality 
improvement program focusing on patients (diagnosed and undiagnosed) at a modifiable 
and higher risk of COPD exacerbations. The first step in CONQUEST was the development 
of quality standards (QS). The QS will be imbedded in routine primary and secondary care, 
and are designed to drive patient-centered, targeted, risk-based assessment and management 
optimization. Our aim is to provide an overview of the CONQUEST QS, including how they 
were developed, as well as the rationale for, and evidence to support, their inclusion in 
healthcare systems.
Methods: The QS were developed (between November 2019 and December 2020) by the 
CONQUEST Global Steering Committee, including 11 internationally recognized experts 
with a specialty and research focus in COPD. The process included an extensive literature 
review, generation of QS draft wording, three iterative rounds of review, and consensus.
Results: Four QS were developed: 1) identification of COPD target population, 2) assess-
ment of disease and quantification of future risk, 3) non-pharmacological and pharmacolo-
gical intervention, and 4) appropriate follow-up. Each QS is followed by a rationale 
statement and a summary of current guidelines and research evidence relating to the standard 
and its components.
Conclusion: The CONQUEST QS represent an important step in our aim to improve care 
for patients with COPD in primary and secondary care. They will help to transform the 
patient journey, by encouraging early intervention to identify, assess, optimally manage and 
followup COPD patients with modifiable high risk of future exacerbations.
Keywords: identification, assessment, intervention, follow-up
Plain Language Summary
Under-diagnosis and under-treatment of COPD results in significantly higher risk of exacer-
bations, morbidity and death. Early identification and appropriate management should 
mitigate that risk. The COllaboratioN on QUality improvement initiative for achieving 
Excellence in STandards of COPD care (CONQUEST) aims to improve the management 
of patients at greater risk of future COPD exacerbations by developing and implementing 
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quality standards (QS) into routine care and measuring implementation success. This is an 
area where important improvements in patient care and outcomes can be made and measured.
Four QS were developed: 1) identification of COPD target population, 2) assessment of 
disease and quantification of future risk, 3) appropriate non-pharmacological/pharmacologi-
cal intervention, and 4) appropriate follow-up. The target population are patients with COPD 
(or potential COPD) with ≥2 moderate, or ≥1 severe exacerbations in the last 24 months (≥1 
of these in the last 12 months) AND with scope for management optimization. Each QS is 
followed by a rationale statement and summary of current guidelines/evidence to support it 
and its components.
These QS represent a first step in empowering primary and secondary care providers to 
identify, assess, quantify risk, treat, and follow-up the millions of people living with COPD 
(both diagnosed and undiagnosed) at increased risk of exacerbations, morbidity and mortal-
ity. By incorporating these QS into routine care, CONQUEST aims to affect sustained change 
to COPD patient care. The QS will be used as a benchmark to monitor the impact of quality 
improvement on COPD outcomes in two planned CRTs in the UK and the USA.
Introduction
Despite being a largely preventable disease, the global burden of chronic obstruc-
tive pulmonary disease (COPD) is high and remains a public health priority in the 
21st century.1 COPD affects approximately 384 million people worldwide and is 
the third leading cause of death.2,3 It is frequently under-diagnosed, under-treated, 
and has high morbidity, including a greater risk of cardiovascular (CV) disease and 
death.3–5 COPD is projected to be responsible for a loss of 45 million quality- 
adjusted life years, 315 million exacerbations, and 9 million deaths cumulatively in 
the USA over the next 20 years, assuming current patterns of treatment and 
smoking rates.6 The socio-economic burden of COPD is also high, with projected 
20-year (2019–2038) discounted direct and indirect costs estimated at $801 billion 
and $101 billion, respectively, in the USA.6 Similarly, the average total annual per 
patient cost of COPD management (excluding medications) in the United Kingdom 
has been estimated at £3396 for those experiencing ≥2 moderate-to-severe exacer-
bations. Primary care associated costs contribute most to overall expenditure.7
COPD is initially managed predominantly in primary care, but key opportunities 
to optimize management are often not realized due to unrecognized disease and 
delayed implementation of appropriate interventions for both diagnosed and 
undiagnosed individuals.8,9 A study carried out in the UK found that opportunities 
for diagnosis were missed in 85% of the patients in the 5 years immediately 
preceding COPD diagnosis.8 As a consequence, many patients receive no treatment 
or delayed initiation of maintenance therapy, even after diagnosis.9 This is impor-
tant since interventions such as smoking cessation and pulmonary rehabilitation10,11 
may improve prognosis and drugs such as inhaled corticosteroids (ICS) may 
improve current symptoms and exacerbations that are associated with rapid lung 
function loss.12 Furthermore, patients who experience a greater exacerbation burden 
after initiation of maintenance therapy have worse lung function at diagnosis and 
a more rapid lung function decline thereafter, emphasizing the need for better 
treatment strategies.13 These findings highlight the importance of earlier interven-
tion among patients with COPD, to more proactively diagnose and manage opti-
mally. Current gaps in COPD management and the need for improved quality of 
care have been recognized both in the UK and the USA.14–18 In the USA, specific 
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goals of the COPD national action plan14 are to raise 
public awareness of COPD, educate key stakeholders in 
diagnosis, prevention, and treatment, and encourage data 
sharing/dissemination. In the UK, the Department of 
Health has similar goals for COPD management.16,18
The COllaboratioN on QUality improvement initiative 
for achieving Excellence in STandards of COPD care 
(CONQUEST) is a new program providing a roadmap to 
improved quality of COPD care,19 and aligns with the aims 
of both the COPD National Action Plan and the UK 
Department of Health. CONQUEST is the first-of-its-kind 
collaborative, interventional, COPD registry with an inte-
grated quality improvement program. Its vision is to drive 
change in the management of patients (both diagnosed and 
undiagnosed) at a greater risk of future COPD exacerbations 
and to measure the success of implementing this change in 
cluster randomized trials. This vision will be achieved by 
closing gaps in current COPD care provision, imbedding 
quality standards (QS) in routine primary care, integrating 
information from these patients, and presenting it to clini-
cians in a way that drives patient-centered, targeted, risk- 
based assessment and treatment optimization, thus empow-
ering both patients and physicians to improve COPD care.19 
The registry will be populated from local and global data 
sources and will hold anonymized data from over 200,000 
primary and secondary care COPD patients (both diagnosed 
and undiagnosed) at modifiable high risk for COPD exacer-
bations. Patients will be identified through, and data col-
lected from, electronic medical records (EMR). These data 
will be further supplemented through patient questionnaires 
and enhanced clinical assessments.19
The first step in the CONQUEST program is the devel-
opment of QS. The aim of this article is to provide an 
overview of the CONQUEST QS, including how they 
were developed, as well as the rationale for, and evidence 
to support, their inclusion.
Methods
Quality Standard Design
These QS are core research and evidence-based statements 
that underpin the CONQUEST initiative and are intended to 
cover care for a targeted COPD population (see CONQUEST 
target patients below), a large proportion of whom may be 
positively impacted by quality COPD care. When developing 
these QS, consideration was given to 1) practicality and ease 
of use by all stakeholders (eg, clinicians, policy makers, 
advocacy groups), 2) future-proofing the QS, by advocating 
general principles rather than a stringent and didactic 
approach, 3) feasibility of implementation in routine clinical 
practice, 4) the need to compare QS adherence and impact on 
disease outcomes across healthcare systems and 5) inter- 
country differences in COPD burden (morbidity, mortality, 
socio-economic), and patterns of treatment and access to 
care. Ethical approval from an Independent Review Board 
was not required as this article outlines QS informed by 
review of evidence in the public domain, no participants 
were recruited and data were neither collected nor analyzed.
The CONQUEST Target Patients
Two CONQUEST groups have been identified: those with 
a COPD diagnosis at baseline and those without a COPD 
diagnosis who fit the modifiable high-risk criteria. Please 
refer to Table 1 for a summary of CONQUEST key terms. 
Modifiable high-risk patients are those with COPD (or 
potential COPD) who have had ≥2 moderate or ≥1 severe 
(hospitalized) exacerbation in the last 24 months (with at 
least one exacerbation occurring in the last 12 months) 
AND whose medical record data clearly indicates scope 
for management optimization. Management optimization 
focuses on patients who continue to have exacerbations 
while on their current therapy (including no therapy or 
short-acting β2-agonist only) and/or whose management 
may be optimized by correct diagnosis or additional non- 
pharmacological interventions. COPD exacerbations are 
defined as a significant worsening in respiratory symptoms 
in people with COPD (or an event analogous to a COPD 
exacerbation in people with suspected but undiagnosed 
COPD) and are categorized as moderate or severe. 
CONQUEST patients are required to be ≥40 years of age 
and, for those with potential COPD, to have a current or 
previous smoking history (ie, current or ex-smokers with 
≥10 pack-year history or ≥10 years smoking duration).
CONQUEST Task Force
The CONQUEST QS task force comprises the Global 
Steering Committee, including 11 internationally recognized 
experts with a specialty and research focus in COPD from 8 
countries across 4 continents, as well as 2 AstraZeneca 
members (Table 2). Membership of the task force was 
weighted towards the UK and the USA as it is in these 
countries where the QS will be initially implemented and 
trialed, before rolling out to other countries. Task force 
members are all experts in the field of COPD. Criteria for 
task force membership included 1) publication history; 2) 
leadership of national or international initiatives that have 
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Table 1 Lexicon of CONQUEST Key Terms
Term Definition
CONQUEST Quality Improvement Program Full name: Collaboration on a Quality Improvement Initiative to Achieve Excellence in 
Standards of COPD Care. The purpose of the CONQUEST program is to improve the 
prompt identification of patients with modifiable high-risk COPD, and to support the 
adoption of guideline-led clinical decision-making for all COPD patients, with a focus on 
assessment, therapy, and follow-up of patients with modifiable high-risk COPD. The 
components of the program form the intervention evaluated in PREVAIL.
PREVAIL Studies
PREVAIL Cluster Randomized Controlled Trial PRagmatic EVAluation of a quality Improvement program for people Living with 
modifiable high-risk COPD. The impact of the CONQUEST program on COPD 
outcomes will be evaluated in the subset of patients with modifiable high-risk COPD by 
a cluster-randomized controlled trial (CRT); self-contained primary care sites (PCS) or 
general practitioner (GP) practices will be the cluster units of randomization.
Baseline Period The 24 months prior to randomization where primary care site (PCS) electronic medical 
record (EMR) data will be retrospectively searched to identify patients meeting 
modifiable high-risk criteria. The term “trial baseline” is used to describe the end of this 
24-month-period, immediately prior to randomization.
Recruitment period The period over which PCSs are recruited, electronic medical record (EMR) data are 
extracted, and sites are randomized to the CONQUEST intervention or control arm.
Implementation period The intervention implementation period (start of the CONQUEST program) follows the 
recruitment period and runs for 6 months during which time the CONQUEST Quality 
Standards are implemented in intervention arm PCSs. This includes invitation of 
modifiable high-risk cohorts for assessment and clinical decision support prompted 
consultations to initiate optimization of COPD management. Control arm PCS continue 
with standard care.
Outcome Evaluation Period Intervention arm site: The outcome evaluation period starts at the end of the 6-month 
CONQUEST implementation period in the intervention arm. During the outcome 
evaluation period control arm practices will continue to administer usual care for COPD. 
Control arm sites: The outcome evaluation period will start 6 months after recruitment 
of a PCS into the control arm. During the outcome evaluation period control arm 
practices will continue to administer usual care for COPD. 
The outcome evaluation period continues until the roll-out of CONQUEST to control 
arm PCSs.
Roll out Roll-out of the CONQUEST intervention to the control arm practices commences at 
the start of the final year (year 5). 
Control arm roll-out mirrors the intervention arm implementation period; PCSs invite 
high-risk cohorts of patients for assessment and clinical decision support prompted 
consultations to initiate optimization of COPD management.
OPC affiliated sites Those healthcare sites participating in the PREVAIL CRT or implementing the 
CONQUEST QI Program with the direct support of OPC.
Independent sites Healthcare systems or sites wishing to implement the CONQUEST QI program (in 
accordance with the Global QI Operational Protocol) who are not supported by OPC 
directly. Independent sites will have access to resources and templates related to the 
program via the Global Operational Protocol and the CONQUEST website.
(Continued)
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Table 1 (Continued). 
Term Definition
CONQUEST Target patients
Modifiable “High-risk” patient Patients with COPD (or potential COPD) who have had 2 or more moderate, or 1 or 
more severe exacerbations in the last 24 months (with at least one exacerbation 
occurring in the last 12 months), AND whose medical record data indicates clearly that 
there is scope for management optimization. 
Patients with frequent exacerbations are at higher future risk of exacerbations. Frequent 
exacerbations are linked to accelerated lung function decline, greater risk of 
cardiovascular events and death. Guidelines state that frequent exacerbators should have 
their treatment optimized to reduce the risk of future exacerbations and potentially 
other adverse events. CONQUEST aims to address the management needs of such 
patients by promoting improved treatment and follow-up.
Undiagnosed patient with potential modifiable 
high-risk COPD
Patients without a COPD diagnosis who fit the modifiable high-risk criteria with respect 
to recent exacerbations of potential COPD, and who are smokers or former smokers ≥ 
40 years of age. 
Exclusion: those with an active asthma diagnosis (ie, with an EMR diagnostic code for 
asthma and evidence of an asthma consultation in the 2 years before randomization 
(PREVAIL) or before identification (CONQUEST QI program)). 
N.B. 50 years of age will be used as the cut-off in the CRT in order to increase probability 
of identifying undiagnosed COPD patients.
Newly diagnosed modifiable high-risk COPD 
patients
The subset of the above undiagnosed patients who receive a COPD diagnosis following 
diagnostic assessment in the most recent CONQUEST QIP cycle. 
OR 
In the PREVAIL CRT, the subset of the above undiagnosed patients who receive a COPD 
diagnosis following assessment during the implementation and outcome evaluation 
period.
Modifiable high-risk COPD diagnosed patients Patients with a COPD diagnosis at baseline who fit the modifiable high-risk criteria with 
respect to recent COPD exacerbations and are ≥40 years of age, and in whom there is 
an opportunity to optimize management.
Patients with scope for management 
optimization in CONQUEST QI program
The intervention will focus on patients who continue to have exacerbations while on 
their current therapy (including no therapy SABA, SAMA or SABA/SAMA only) and/or 
whose management may be optimized by correct diagnosis, or additional non- 
pharmacological interventions such as smoking cessation interventions or pulmonary 
rehabilitation.
Exacerbations
COPD exacerbation (EMR database definition) A significant worsening in respiratory symptoms in people with COPD. 
Either a moderate exacerbation defined as requiring an acute course of systemic 
corticosteroids and/or a course of antibiotics within 3 days of a lower respiratory 
consultation indicative of a probable COPD exacerbation, or an emergency room visit 
for a COPD-related respiratory cause*; or a severe exacerbation – ie an exacerbation 
resulting in a hospital admission or death from a COPD-related respiratory cause*.117 
Exacerbations occurring a minimum of 7 days after treatment of the initial exacerbation 
has ended will be considered as separate exacerbations. Prescribing instructions held in 
the EMR record will be used to identify the end of an exacerbation (ie, using recorded 
information on the duration of the treatment).
(Continued)
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Table 1 (Continued). 
Term Definition
Exacerbation of potential COPD 
(EMR database definition)
A significant worsening in respiratory symptoms analogous to a COPD exacerbation in 
people with suspected but undiagnosed COPD. 
Either a moderate potential exacerbation defined as requiring an acute course of 
systemic corticosteroids and/or a course of antibiotics within 3 days of a lower 
respiratory infection consultation, or an emergency room visit for a potentially COPD- 
related respiratory cause†; or a severe exacerbation – ie an exacerbation resulting in 
a hospital admission or death for a potentially COPD-related respiratory cause†. 
Exacerbations occurring a minimum of 7 days after treatment of the initial exacerbation 
has ended will be considered as separate exacerbations. Prescribing instructions held in 
the EMR record will be used to identify the end of an exacerbation (ie, using recorded 
information on the duration of the treatment).
Complicated exacerbation A severe COPD exacerbation 
OR 
A moderate COPD exacerbation involving any of the following: 
Additional acute course(s) of corticosteroids and/or respiratory antibiotic between 8 and 
28 days after the initial event. 
Further record of moderate/severe COPD exacerbation between 8 and 28 days after the 
start of the initial event.
Other
Systemic steroid burden Total annual corticosteroid exposure from oral tablets, intravenous injection, or 
intramuscular injection measured as the average annual dose of prednisolone taken via 
any route, in milligrams. 
Records of systemic steroids other than prednisolone will be converted to prednisolone 
equivalent doses using USA and UK national formulary conversion tables.118,119
MACRE 
Major adverse cardiac or respiratory event
Occurrence of any of the below events: 
New diagnosis for heart failure, Hospitalization for heart failure, Revascularization, 
Myocardial Infarction, Stroke, All-cause mortality (further categorized as sudden death, 
cardiac deaths, respiratory death, none of these), Hospitalization or hospital admittance 
for respiratory event*, or Complicated exacerbations.
Collation of PRO/PRI questionnaire data In patients receiving the QIP, PRO/PRI instruments will be completed at least annually, 
bringing together data received during the implementation of the intervention to be used 
in annual data analysis and feedback.
Opportunity Analysis Retrospective study using EMR data to assess the management of patients with 
modifiable high-risk COPD over time in primary care and describe opportunities for 
management optimization in line with the Quality Standards. An opportunity analysis will 
be conducted in both the USA and the UK.
Notes: *Identified using validated code lists for moderate and severe COPD exacerbations. †Algorithm developed to define moderate and severe potential COPD 
exacerbations using appropriate respiratory diagnostic, symptom and investigation codes. 
Abbreviations: CONQUEST, COllaboratioN on a QUality improvement initiative to achieve Excellence in STandards of COPD care; COPD, chronic obstructive 
pulmonary disease; EMR, electronic medical record; CRT, cluster randomized controlled trial; GOLD, Global initiative for chronic Obstructive Lung Disease; GP, general 
practitioner; ICS, Inhaled Corticosteroids; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; MACRE, Major Adverse Cardiac or Respiratory Event; 
OPC, Optimum Patient Care; PCS, primary care site; PREVAIL; PRagmatic EVAluation of a quality Improvement program for people Living with modifiable high-risk COPD; 
PRO/PRI, patient-reported outcome/patient-reported information; QIP, Quality Improvement Program; SABA, short-acting β2-agonist, SAMA, short-acting muscarinic 
antagonist.
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focused on high-risk COPD patients; or 3) experience as 
a primary care medical provider, patient representative or 
with cardiology expertise. Their role is to provide scientific 
advice on CONQUEST research projects and quality 
improvement program implementation, and to ensure that 
CONQUEST research is ethical, clinically appropriate, and 
continues to bring value to patients and physicians.
Quality Standard Development
The process included an extensive literature review as well 
as discussions with, and consensus of, experts of the 
CONQUEST Global Steering Committee and is summar-
ized in Figure 1. Eight QS were initially identified, pre-
dominantly based on the National Institute for Health and 
Care Excellence (NICE) and Global initiative for chronic 
Table 2 Members of the CONQUEST Quality Standard Task Force
Member Affiliation
Dr Luis Alves (Portugal) Institute for Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal
Professor Rongchang Chen (China) Director of Guangzhou Institute of Respiratory Diseases
Dr Mark Dransfield (USA) Associate Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine
Professor John Hurst (UK) Professor of Respiratory Medicine, University College London
Dr Fernando Martinez (USA) Chief of Division of Pulmonary and Critical Care (GOLD committee)
Dr Marc Miravitlles (Spain) Pulmonologist, clinical research, Hospital Universitari Vall D’Hebron, Barcelona
Professor Shigeo Muro (Japan) Professor of Respiratory Medicine, Nara Medical University, Japan
Professor David Price (Singapore) Observational and Pragmatic Research Institute, Singapore
Dr Anita Sharma (Australia) GP with cardiovascular interest at Platinum Medical Centre, Chair Scientific Programme Committee IPCRG
Professor Dave Singh (UK) Professor of Clinical Pharmacology & Respiratory medicine, University of Manchester (GOLD committee)
Tonya Winders (USA) President and Chief Executive Officer of Allergy & Asthma Network
Hana Müllerová Medical Evidence Lead for COPD, AstraZeneca
Chris Blango Employee of AstraZeneca at the time of the manuscript development
Abbreviations: IPCRG, International Primary Care Respiratory Group; GOLD, Global initiative for chronic Obstructive Lung Disease.
Figure 1 CONQUEST quality standards development process. 
Abbreviations: BEC, blood eosinophil count; CONQUEST, COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care; COPD, 
chronic obstructive pulmonary disease; GOLD, Global initiative for chronic Obstructive Lung Disease; GSC, Global Steering Committee; NICE, National Institute for Health 
and Clinical Excellence; OPC, optimum patient care; QS, quality standard.
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Obstructive Lung Disease (GOLD) recommendations, but 
also informed by the American Thoracic Society (ATS)/ 
European Respiratory Society guidelines.3,20–22 Relevant 
references cited within these guidelines were also 
reviewed in addition to research identified through litera-
ture review.3,25–27 These eight QS were prioritized, con-
solidated (following several rounds of review by Optimum 
Patient Care medical experts) and sent to the CONQUEST 
QS Task Force for review and comment. The process 
consisted of three iterative rounds, and consensus was 
achieved following several meetings and via email corre-
spondence. The process began in November 2019 and 
concluded in December 2020.
Global steering committee consensus was achieved for 
each of the four CONQUEST QS. Each QS is followed by 
a short statement explaining the rationale behind it and 
a summary of current guidelines and research evidence 
relating to the standard and its components.
Results
Quality Standard 1: Identification of 
Target Population
Identify individuals ≥40 years of age (with or without 
a pre-existing COPD diagnosis) with a history of smoking 
or relevant environmental exposure, at increased risk of 
exacerbations, morbidity, and mortality and with scope for 
COPD management optimization.
And, within this population, identify those with greater 
cardiovascular risk (Figure 2).
Rationale
The lives of COPD patients are significantly impacted by 
the disease. This informed the CONQUEST decision to 
focus our efforts on those individuals (both diagnosed and 
undiagnosed) at risk of exacerbating and to intervene ear-
lier in the COPD journey in order to slow the speed of 
COPD progression (eg, accelerated lung function decline, 
increased exacerbation frequency, deterioration in co-mor-
bidity control). A focus on patients at higher risk of 
exacerbating is an area in which large and important 
improvements in patient care and outcomes can be made 
and measured. These patients require more intense focus 
on identification and assessment in order to optimize man-
agement. The goal of optimized management is to reduce 
the number of exacerbations and consequent lung function 
decline and disease progression, thereby improving patient 
health-related quality of life (HRQoL) and decreasing CV 
risk associated with exacerbations.
Supporting Evidence
Evidence to support QS 1 is summarized in Table 3 and 
described in more detail here.
1. Diagnostic delay: COPD diagnosis is often 
delayed.8,23 Data from the Optimum Patient Care 
Research Database found that 85% of patients had 
consulted primary or secondary care for lower respira-
tory symptoms in the 5 years prior to their diagnosis, 
and 58% had consulted in the 10 years prior to 
diagnosis.8 Diagnosing COPD early (feasibly 5–10 
Figure 2 CONQUEST quality standards for the identification and management of patients with COPD at risk of exacerbations or acute respiratory events. 
Abbreviations: CONQUEST, COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care; COPD, chronic obstructive 
pulmonary disease.
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years earlier based on UK data)8 in the disease pro-
gression is important, since undiagnosed patients have 
an increased risk of exacerbations and pneumonia, 
compared to their non-COPD counterparts.24 Use of 
a targeted approach (focused case-finding methods) 
using characteristics such as age, smoking history, and 
respiratory symptoms may help to find these undiag-
nosed COPD patients.25,26 Physicians are more than 
seven times more likely to detect undiagnosed COPD 
in the targeted group (vs a routine care group), trans-
lating into one new case identified for every 21 tar-
geted individuals assessed (after risk difference 
adjustment).26 Undiagnosed patients who present to 
their health care provider (HCP) form part of the 
target population for CONQUEST, particularly those 
with a smoking history, who consult with lower 
respiratory symptoms, who received medication for 
lower respiratory illness or who were admitted to 
hospital or treated in an outpatient setting with respira-
tory symptoms.
2. Management optimization: COPD often remains 
undertreated, with a gap between guideline recom-
mendations and real world practice.9,27,28 Medical 
and pharmacy claims data in the USA found that 
>65% of COPD patients were receiving no main-
tenance therapy,27 whereas in the UK, three quarters 
of patients with a modified Medical Research 
Council (mMRC) dyspnea score <2 but ≥2 exacer-
bations/year were considered under-treated.9 
Although patients hospitalized with severe exacer-
bations usually receive recommended care, once 
discharged, most patients receive inappropriate sup-
port and medications.29
3. Exacerbation frequency: Many patients with COPD 
experience ≥2 exacerbations/year.30 For example, 
22% of patients with moderate COPD had frequent 
exacerbations in the ECLIPSE study.31 
Furthermore, real-world data found that COPD 
patients who had ≥2 lower respiratory prescribing 
consultations in the 2 years preceding diagnosis 
were over three times more likely to have ≥2 
exacerbations in the year after diagnosis.8 Earlier 
identification and treatment of patients who fre-
quently exacerbate is likely to protect lung function, 
reduce CV risk and improve patients’ HRQoL since 
1) frequent exacerbations accelerate lung function 
decline,12,32 2) exacerbations of COPD increase the 
risk of major adverse CV events,33–36 and 3) 
frequency of exacerbation is associated with worse 
HRQoL.37,38 COPD patients with CV disease are 
four times more likely to have a subsequent CV 
event if they exacerbate, and 10 times more likely 
to have a subsequent CV disease (eg, cardiovascular 
death, myocardial infarction, stroke, unstable 
angina or transient ischemic attack) if the exacerba-
tion required hospitalization.36
Quality Standard 2: Assessment of 
Disease and Quantification of Future Risk
Perform thorough phenotyping, assessment of underlying 
biological traits and risk prediction of all patients identi-
fied within the target population (Figure 2).
Rationale
Different COPD phenotypes require different therapeutic 
interventions. Thorough assessment will enable accurate 
individual prediction of future risk of exacerbations, dis-
ease progression, mortality and CV risk, with the goal to 
guide therapy.
The assessment of individuals with COPD (both diag-
nosed and undiagnosed) with modifiable high risk of mor-
bidity (including exacerbations) and mortality should include 
assessment of 1) symptoms and exacerbation history, 2) 
spirometry and other measures of lung function, 3) body 
mass index (BMI), 4) blood eosinophil count (BEC), 5) 
chest imaging, 6) cardiovascular risk assessment, 7) identifi-
cation of co-morbidities, 8) use of relevant risk prediction 
tools and 9) smoking exposure and physical activity.
Supporting Evidence
Evidence to support QS 2 is summarized in Table 3 and 
described in more detail here.
1. Symptoms: NICE guidelines recommend the use of 
the MRC dyspnea scale for grading breathlessness at 
annual follow-up and when diagnosing COPD (in 
conjunction with other symptoms). The COPD 
Assessment Test is a method of assessing symptom 
burden in COPD that incorporates common 
symptoms.20,22 The results of symptom assessment 
measures can be used to guide pharmacological ther-
apy in accordance with GOLD recommendations.3
2. Post-bronchodilator spirometry: Recommended in 
clinical guidelines to be used in conjunction with 
clinical assessment to confirm the diagnosis of 
COPD,3,22 and is incentivized as part of the 
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Quality Outcomes Framework in the UK. 
Longitudinal spirometry results can be used to mea-
sure lung function decline and response to therapy 
and can help guide therapy interventions.3,12
3. Body mass index: BMI is associated with COPD 
prognosis,20 and included in several risk prediction 
tools and models to determine exacerbation risk and/ 
or mortality risk.39,40 Low BMI (ie, <21.75 kg/m2) 
has been associated with increased risk of pneumo-
nia and mortality in COPD patients.41,42 Obesity, 
with BMI >30 kg/m2, is a risk factor for the devel-
opment of type II diabetes,43 a relevant comorbidity 
for those who frequently exacerbate and require oral 
corticosteroids (OCS).
4. Blood eosinophil count: In stable COPD, BEC is 
recommended as a marker of steroid responsiveness, 
with higher BEC used as an indicator for ICS 
therapy.3,25,27 This recommendation is informed by 
the fact that those with higher BEC have less exacer-
bations when treated with ICS/long acting β2-agonist 
(LABA) versus LABA alone,44,45 or with ICS/LABA/ 
long acting muscarinic agonist (LAMA) vs LAMA/ 
LABA.46–48 Similarly, ICS are beneficial in reducing 
the number of exacerbations in those with elevated 
BEC, with exacerbation rate reductions increasing 
with increasing BEC.49 Real-life data also showed 
that elevated BEC was associated with better outcomes 
for those on triple therapy (vs dual bronchodilator 
therapy),50 and in frequent exacerbators is associated 
with more rapid lung function decline.12 Higher BEC 
(ie, >200 cells/µL) may also be a predictor of OCS 
success in those experiencing exacerbations,51 and 
eosinophil guided therapy has been shown to reduce 
OCS exposure in patients admitted to hospital with 
acute exacerbation of COPD.52 Taken together, these 
results suggest the value of BEC to tailor treatments to 
specific COPD phenotypes and endotypes. However, 
BEC is commonly not available and/or underused in 
primary care and is not routinely considered in treat-
ment decisions. More work on implementation in 
everyday clinical care is needed.
5. Imaging: Such as chest x-ray or CT scan is useful in 
suspected and/or confirmed COPD to exclude other 
respiratory pathologies.3,20 Chest CT scans are neces-
sary when considering lung volume reduction,3,25 for 
the detection of bronchiectasis and for those requiring 
lung cancer assessment.3 CT chest scans (paired insp- 
exp) can aid early diagnosis of COPD by identifying 
air trapping, and standard CT scans can identify airway 
wall thickening, and can discriminate between emphy-
sematous and non-emphysematous phenotypes.53,54 
The former is a predictor for reduced survival as is 
pulmonary artery:aorta ratio.55 However, it is recog-
nized that CT scanning in all patients with COPD may 
not be feasible in the real-life setting.
6. CV risk assessment: CV diseases are perhaps the 
most important co-morbidities in COPD and carry 
an increased risk of death and hospitalization.5,56 
COPD patients have a twofold higher risk of having 
CV disease (including ischemic heart disease, 
arrhythmias and heart failure) than their non-COPD 
counterparts.57 Furthermore, cardiac mortality in 
patients with moderate COPD is higher than mortal-
ity due to respiratory failure,58 and prognosis follow-
ing an acute cardiac event is worse for those who 
also have a diagnosis of COPD.35
7. Identification of co-morbidities: Co-morbidities 
besides CV disease (eg, anxiety/depression, gastroeso-
phageal reflux disease, diabetes mellitus, and osteo-
porosis) are common in COPD and may be 
encountered at any level of disease severity.3,9,59 
These co-morbidities are associated with a higher 
COPD symptom burden, higher likelihood of exacer-
bations and reduced therapy compliance.60 Although 
the GOLD strategy document advises that, in general, 
the presence of co-morbidities should not change 
COPD treatment, these comorbidities can have 
a significant impact on disease course.3
8. Risk prediction tools: For example, the BODE 
index, which integrates BMI, airflow limitation 
(forced expiratory volume in one second (FEV1)), 
dyspnea and 6-minute walk distance, are useful to 
predict COPD mortality.61 Another multicomponent 
index, DOSE (dyspnea, obstruction, smoking, 
exacerbations), has been shown to identify COPD 
patients with a greater risk of future worsening in 
health status and exacerbations.62,63 Others have 
found that risk of developing COPD in adulthood 
can be identified using lifetime lung function trajec-
tory patterns and is 57% greater in those individuals 
with a parental history.64,65 These risk prediction 
tools may be used to guide therapy and highlight 
those most at risk of exacerbations, disease progres-
sion, and mortality within the target population.
9. Smoking (tobacco, e-cigarette/vaping), exposure and 
physical activity: The NICE guidelines suggest 
https://doi.org/10.2147/COPD.S313498                                                                                                                                                                                                                               
DovePress                                                                                              
International Journal of Chronic Obstructive Pulmonary Disease 2021:16 2310
Pullen et al                                                                                                                                                            Dovepress

















































































a multifactorial approach to assess risk of exacerba-
tions including ongoing smoking, exposure to pollu-
tants, infection, insufficient physical activity, seasonal 
variation and frequency of exacerbations.20 GOLD 
acknowledge that smoking cessation is key for 
COPD prevention and for maintenance therapy. 
However, the effectiveness of e-cigarettes as 
a smoking cessation aid is uncertain since e-cigarette 
use has been associated with severe acute lung injury, 
eosinophilic pneumonia, alveolar hemorrhage, respira-
tory bronchiolitis and other lung abnormalities.3,66,67
Quality Standard 3: Non-Pharmacological 
and Pharmacological Intervention
Target therapeutic interventions according to individual 
risk assessment and biological traits (Figure 2).
Rationale
Both non-pharmacological and pharmacological interven-
tions are essential for effective COPD management. These 
are used to reduce symptoms, reduce the frequency and 
severity of exacerbations, and improve exercise tolerance 
and health status.3 In accordance with published literature 
and expert opinion, the GOLD strategy document, and 
NICE and ATS guidelines, the CONQUEST program 
recommends the following3,22:
Non-Pharmacological Interventions 
1. Smoking cessation interventions as appropriate
2. Pulmonary rehabilitation referrals, where indicated
3. Long-term oxygen therapy, where indicated
4. Pneumococcal and annual influenza vaccination to 
all with COPD
5. Patient motivation and engagement enhanced by 
patient-reported outcome information and shared 
decision-making.
Pharmacological Interventions 
1. Dual bronchodilators (LABA/LAMA) to all who are 
symptomatic on long-acting bronchodilator 
monotherapy.
2. Triple therapy (ICS/LABA/LAMA) for appropriate 
patients with exacerbations and elevated BEC, and 
potentially to those with greater CV disease risk and 
greater risk of mortality (ie, severe exacerbations).
a. In line with national guidelines for initial and 
follow-up therapy. Follow-up therapy should 
reflect both background therapy, symptom 
response and exacerbation risk based on actual 
exacerbations and COPD control.
3. Adequate and prompt pharmacological therapy of 
cardiac risk factors and disease according to latest 
guideline recommendations.
4. Regularly assess inhaler choice and technique.
5. Short courses of OCS and/or antibiotics during 
exacerbations as per GOLD or other national/inter-
national guideline recommendations.
Supporting Evidence
Evidence to support QS 3 is summarized in Table 3 and 
described in more detail here.
Non-Pharmacological Interventions 
1. Smoking cessation: Has the greatest capacity to 
influence the natural history of COPD. The earlier 
smoking cessation is achieved the greater the impact 
on preventing lung function decline.68 There is also 
an associated reduction in symptoms following 
smoking cessation.69
2. Pulmonary rehabilitation: Improves dyspnea, health 
status and exercise tolerance in stable patients.3,10,11 
Started soon after an exacerbation of COPD, pul-
monary rehabilitation is safe, effective and asso-
ciated with fewer subsequent hospital admissions 
for exacerbations.70 It is recommended by NICE to 
all “who view themselves as functionally disabled 
by COPD (usually MRC of grade 3 or above)”,25 
and by GOLD as part of integrated COPD patient 
management.3
3. Long-term oxygen therapy: Has been shown to 
increase survival in patients with severe resting 
hypoxemia. GOLD recommend it for patients who 
have 1) PaO2 ≤7.3 kPa or SaO2 ≤88% with or 
without hypercapnia confirmed twice over 
a 3-week period or 2) for those with PaO2 7.3–8.0 
kPa or SaO2 of 88% if there is evidence of pulmon-
ary hypertension, peripheral edema suggesting con-
gestive cardiac failure or polycythemia (hematocrit 
>55%).3 Domiciliary non-invasive ventilation has 
proven utility in those with more severe disease.71
4. Vaccination: NICE and GOLD recommend offering 
pneumococcal and annual influenza vaccination to 
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all with COPD.3,20 More recently, people with more 
severe COPD have been prioritized for COVID-19 
vaccine, and as these become available, local 
recommendations should be followed. Influenza 
vaccinations have been shown to reduce death and 
illness, such as lower respiratory tract infections, in 
COPD patients.72,73 An updated Cochrane review 
also concluded that inactivated influenza vaccine led 
to fewer COPD exacerbations, but noted that there 
were a limited number of randomized controlled 
trials available on the topic.74 Pneumococcal vacci-
nation also reduces the likelihood of COPD 
exacerbation.75 While not currently part of any 
COPD guidelines, there has been some recent dis-
cussion regarding the role of pertussis booster vac-
cination in COPD patients, due to a resurgence of 
pertussis and evidence that COPD patients are at 
high risk of contracting the disease.76
5. Patient motivation and engagement: GOLD recog-
nizes the benefit of personalized, multi-component, 
education and training for patients with COPD 
(rather than simply providing information and 
advice).3 Shared decision-making and patient 
engagement have been shown to significantly 
improve perceived health status, COPD knowledge, 
adherence to pharmacological treatment, general 
functionality and healthy lifestyle measures for 
COPD patients hospitalized for acute 
exacerbations.77
Pharmacological Interventions 
The GOLD strategy document classifies COPD patients 
initiating therapy into ABCD groups based on health status 
as assessed by CAT, mMRC dyspnea score and exacerbation 
history, and recommends appropriate targeted pharmacolo-
gical intervention for each group.3 The CONQUEST cohort 
are likely to fall within GOLD groups C or D. A dyspnea or 
exacerbation directed step up approach is advised if response 
to this initial treatment is not sufficient. Patients with dyspnea 
as their predominant symptom should be stepped up to dual 
LABA/LAMA (if on LABA or LAMA monotherapy) and 
consider switching inhaler device or investigation of other 
causes of dyspnea for those who remain symptomatic on dual 
bronchodilators.3 De-escalation of ICS should only be con-
sidered for those who become low risk over time or have 
reasons to be cautious of ICS use, including low eosinophil 
count and pneumonia.3,78 Exacerbating patients on LABA or 
LAMA mono-therapy should be stepped up to LABA/ 
LAMA or ICS/LABA (if BEC≥300 or BEC ≥100 plus ≥2 
exacerbations), and then to triple therapy if response is 
insufficient.3
1. Dual bronchodilators (to all who are symptomatic on 
long-acting bronchodilator monotherapy): Multiple 
studies have found improvements in lung function, 
symptoms and HRQoL with dual bronchodilators 
when compared to single therapy or placebo.79
2. Triple therapy (ICS/LABA/LAMA) for appropriate 
patients with exacerbations and higher BEC, and 
potentially to those with greater CV disease risk 
and greater risk of mortality): Most beneficial to 
symptomatic COPD patients with an exacerbation 
history despite dual therapy. Also recommended for 
those patients with higher BEC (ie, ≥300 cells/ 
µL).80,81 COPD patients with a history of exacerba-
tions treated with triple therapy experienced better 
HRQoL, better lung function and fewer moderate- 
to-severe exacerbations, compared to those treated 
with either LABA/LAMA or ICS/LABA; with 25% 
and 16% less exacerbations, respectively.82 ICS- 
containing regimens were associated with a lower 
rate of death from CV and respiratory causes and 
lower all-cause mortality.82,83 However, in keeping 
with other studies,84,85 an increased incidence of 
pneumonia was noted for those on ICS.82 For exam-
ple, studies of salmeterol/fluticasone in COPD 
found that the number needed to treat to induce 
one case of pneumonia ranged from 16 to 20.86 
More recently, the ETHOS study also found that 
compared to those on dual therapy, patients on ICS 
triple therapy experienced a significantly lower 
annual exacerbation rate (budesonide/glycopyrro-
nium/formoterol) vs LAMA/LABA: (number 
needed to treat) (NNT)=3 and vs ICS/LABA: 
NNT=7],87 with lower mortality rates (any cause) 
noted in the higher ICS group.47 Pneumonia rates 
across triple and dual therapies were low, between 
0.02 and 0.05 per patient-year and were lower for 
budesonide/glycopyrronium/formoterol than bude-
sonide/formoterol (number needed to harm=58), 
suggesting a low pneumonia risk for budesonide/ 
glycopyrronium/formoterol relative to its benefits 
on exacerbations.87
3. Adequate and prompt pharmacological therapy of 
cardiac risk factors and disease: Although CV med-
ications can cause concerns among prescribers over 
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possible side effects or interactions in COPD 
patients leading to under-treatment of CV 
disease,88 the overall principle advocated by current 
COPD guidelines is that treatment of comorbidities 
should not be altered by the presence of COPD.3 
The use of cardio-selective β1-blockers where indi-
cated in ischemic heart disease and heart failure is 
considered safe with the benefits of treatment out-
weighing any potential risks.89 The current GOLD 
report advises that heart failure should be treated no 
differently in COPD patients and use of cardio- 
selective β-blockers is recommended.3
4. Regularly assess inhaler choice and technique: While 
ensuring the right drug is prescribed to the patient at 
the correct dose is important for treatment success, 
method of delivery and inhaler training are often 
overlooked. Choice of inhaler should be tailored to 
the individual patient where possible and considera-
tion given not only to what the inhaler contains (eg, 
drug class/particle size) but also inspiratory flow, ease 
of use, patient preference, age, cognition, manual 
dexterity and coordination.90 Regular checking of 
inhaler technique is also important and has been 
associated with improved therapy adherence.91
5. Short course of OCS for exacerbations (when clinically 
indicated): GOLD strategy suggests consideration of 
a course of OCS of between 5 and 7 days for moderate 
or severe acute exacerbations.3 Use of OCS in these 
situations is associated with improved lung function, 
oxygenation and recovery time.92 Similarly for those 
with raised BEC, treatment with OCS during an acute 
exacerbation has been associated with a reduction in 
treatment failure and hospitalization.51 The NICE 
guidelines also recommend short-term OCS use (typi-
cally 5 days) in all people admitted to hospital with an 
exacerbation of COPD (if no contraindications) and to 
consider their use in community settings when an 
exacerbation is associated with “a significant increase 
in breathlessness that interferes with daily activities”.13 
OCS can be associated with significant side effects in 
both the short and long term.93
Quality Standard 4: Appropriate 
Follow-Up
Ensure regular follow-up to address non-pharmacological 
and pharmacological intervention by symptoms review and 
assessing risk prediction and lifestyle risk factors (Figure 2).
Rationale
Ongoing effort over time is required to change beha-
vior and determine the appropriate course of therapy. 
Not all aspects of COPD care can be discussed and 
addressed in an initial consultation or risk assessment 
and therefore require a long-term patient treatment 
strategy.
Supporting Evidence
Evidence to support QS 4 is summarized in Table 3 and 
described in more detail here.
To improve quality of care for COPD patients, efforts to 
provide individualized treatment plans and interventions 
must be ongoing.3 This cycle of ongoing review and assess-
ment involves pharmacological, clinical, and non-pharmaco-
logical components as outlined below:
1. Medication, inhaler device and symptom review: 
Current therapy should be recorded and reviewed with 
up-to-date biomarkers, spirometry, symptom severity 
scores and exacerbation rates. Pulse oximetry (at rest, 
during a 6-minute walk or overnight) can be used to 
estimate a patient’s arterial oxygen saturation and need 
for supplemental oxygen therapy, and is important in all 
patients with clinical signs suggestive of respiratory 
failure or right heart failure.3 Use of the COPD control 
tool may help to achieve appropriate and faster clinical 
review to evaluate response to therapy and escalate 
treatment where appropriate.94,95
2. Inhaler technique: There is evidence that errors in 
inhaler technique are associated with worse disease 
outcomes in both asthma and COPD.96 Conversely, 
significant improvement in inhaler technique has been 
associated with improved COPD control,97 and check-
ing of inhaler technique (within the last 2 years) is 
associated with better adherence.91
3. Smoking cessation: A Cochrane review in 2016 found 
evidence that smokers with COPD were more than 
twice as likely to quit if they received “high-intensity 
behavioral support” as well as medication, compared 
to those receiving only behavioral support.98 There 
was no clear evidence that any one form of support 
or medication was better than another.
4. Nutrition: NICE COPD guidelines recommend cal-
culation of BMI at the time of diagnosis and at 
follow-up, and referral for dietetic advice is recom-
mended for those with low or high BMI.20
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5. Pulmonary rehabilitation: Patient needs and 
requirements can change over time, so the role of 
pulmonary rehabilitation should be part of regular 
patient follow-up. Patients should be referred if the 
therapy is likely to be beneficial. Considerations 
regarding patients suitable for referral include dis-
cussion of patient goals and their ability to perform 
the exercises, as well as noting the need to commit 
to a course of therapy lasting at least 6 to 8 
weeks.3,99 The likely benefits of the program 
should be emphasized to the patient. The ability 
of clinicians to refer patients to a suitable pulmon-
ary rehabilitation program may be limited by 
resources and availability.
6. Vaccination: Should be offered to COPD patients at 
review in accordance with local policies (please also 
see point 4 of QS 3 supporting evidence for non-phar-
macological intervention).
Table 3 COPD Quality Standards and Rationale for Their Inclusion in CONQUEST
Quality Standard Rationale to Include as a CONQUEST QS
1. Identification COPD diagnosis is often delayed in primary care.8,23 
Use of a targeted approach on ‘at risk’ patients can help to find these undiagnosed COPD patients.25,26 
COPD remains undertreated, with a gap between guideline recommendations and real world 
practice.9,27,28 
COPD exacerbations are associated with accelerated lung function decline,12,32 and increased risk of 
major adverse CV events,33–36 and worse HRQoL.37,38 
The socio-economic burden of COPD is high.6,7
2. Assessment of disease and risk 
quantification
Symptom assessment using mMRC and or CAT score and exacerbation history to inform and guide 
therapy.3 
BEC is recommended as one marker of steroid responsiveness in stable COPD.3,25,27 
CV disease in COPD patients carries an increased risk of death and hospitalization.5,56 
Other co-morbidities (eg, anxiety/depression, GERD, DM, Osteoporosis) are associated with a higher 
COPD symptom burden, higher likelihood of exacerbations and reduced therapy compliance.60
3. Non-pharmacological and 
pharmacological interventions
CONQUEST recommends:3 
Smoking cessation interventions as necessary. 
Pulmonary Rehabilitation referrals where indicated. 
Long-term oxygen therapy where indicated. 
Dual bronchodilators to all who are symptomatic despite being on single therapy. 
Triple therapy for appropriate patients with increased exacerbation risk, higher BEC, and potentially to 
those with greater CV disease risk. 
Adequate and prompt pharmacological therapy of cardiac risk factors and disease. 
Appropriate inhaler choice and checking of inhaler technique. 
Appropriate use of OCS and antibiotics to treat exacerbations. 
Pneumococcal and annual influenza vaccination to all with COPD and Covid-19 vaccination according 
to local recommendations.
4. Follow-up GOLD recommends that current therapy should be recorded and reviewed with up-to-date 
biomarkers, post-bronchodilator spirometry, symptom severity scores and exacerbation rates.3 
Pulse oximetry used to evaluate the need for supplemental oxygen therapy.3 
Errors in inhaler technique are associated with worse disease outcomes.96 
Smokers with COPD are > twice as likely to quit if they received ‘high-intensity behavioral support’.98 
NICE COPD guidelines recommend calculation of BMI at the time to diagnosis and at follow-up, and 
referral for dietetic advice is recommended for those with low or high BMI.20 
Patient needs and requirements can change over time, so the role of PR should be part of regular 
patient follow-up. 
NICE and GOLD recommend pneumococcal and influenza vaccination to all with COPD.3,25
Abbreviations: BEC, blood eosinophil count; BMI, body mass index; CONQUEST, COllaboratioN on QUality improvement initiative for achieving Excellence in STandards 
of COPD care; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; DM, diabetes mellitus; GERD, gastroesophageal reflux 
disease; GOLD, Global initiative for chronic Obstructive Lung Disease; HRQoL, health-related quality of life; mMRC, modified Medical Research Council breathlessness 
score; NICE, National Institute for Health and Clinical Excellence; OCS, oral corticosteroid; PR, pulmonary rehabilitation.
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7. Motivation and engagement: For quality improvement 
initiatives of this kind to be successful, there must be 
motivation to drive long-term behavioral changes, 
from both the physician/clinical team and the patient. 
In the past, therapeutic nihilism has been a feature of 
COPD care, but there is evidence that this feeling that 
little can be done for COPD patients is changing, with 
improving primary care physician knowledge and 
awareness of COPD guidelines.100 Ensuring that moti-
vation is sustained beyond the trial phase is a critical 
part of the CONQUEST initiative. Patients may not be 
motivated to seek medical help due to a lack of under-
standing of the disease itself, feelings of guilt and 
stigma associated with a COPD diagnosis,101,102 the 
feeling that it is “too late” to change or simply due to 
ignoring symptoms and/or attributing them to another 
cause.103,104 Greater public awareness and knowledge 
of the condition and the possibilities for its treatment 
are needed to counter these issues. Implementing 
behavior-targeted interventions with the aim of 
improving physical activity should also be considered 
as physical activity is often significantly reduced in 
COPD patients.105 According to GOLD (2021),3 “This 
can lead to a downward spiral of inactivity, predispos-
ing patients to reduced QoL, increased rates of hospi-
talization and mortality”.106,107
Discussion
These CONQUEST QS represent a roadmap to improved 
quality of care for people with COPD (both diagnosed and 
undiagnosed). People with modifiable disease and higher 
risk of exacerbations, morbidity and mortality, are indivi-
duals for whom there is an opportunity to optimize man-
agement. The QS presented in the current article represent 
a first step in empowering primary and secondary care 
providers to identify, assess, quantify risk, treat, and fol-
low-up the millions of people living with COPD who fall 
into this category, and differ from previous QS in that they 
are internationally agreed. They are important, as better 
identification of those at risk of exacerbating and those 
requiring management optimization is needed to reduce 
lung function decline and disease progression and improve 
patient HRQoL. Phenotyping disease using clinical, CV 
risk and biomarker variables should facilitate the identifi-
cation of treatable traits, bringing us one step closer to the 
practice of precision medicine and selection of targeted 
phenotype-specific treatments to optimize COPD out-
comes. Finally, regular follow-up of COPD patients is 
critical to modify risks (with appropriate diagnosis and 
treatment), lock in behavior change(s), measure treatment 
successes, and encourage re-assessment of the patient (eg, 
identification of clinical, non-pharmacological and phar-
macological interventions/issues, making adjustments to 
treatment when necessary). By engaging physicians and 
patients, and then incorporating and embedding a process 
of quality improvement into routine care, we aim to bring 
about sustained change to COPD patient care. The QS will 
be used as benchmark to monitor the impact of quality 
improvement in COPD management.
Although, many of the components of our initiative 
may be intuitive, data showing that it can be implemented 
successfully, in a way which can be scaled up globally, and 
improve disease outcomes is less apparent. Other initia-
tives to improve quality of care and guideline adherence in 
COPD management have shown some success.17,108–115 
Specific quality improvement initiatives have included 
financial incentives,108 national clinical audits,17 COPD 
diagnosis questionnaires,109 educational programs for 
patients and physicians,111,114 introduction of care bundles 
to COPD management112 and utilization of EMR for clin-
ical decision-making support.110 For example, introduction 
of a COPD flow sheet into EMR at a tertiary care clinic 
resulted in significant improvement of clinical assessment 
and use of LABA.110 Use of a web-based disease manage-
ment system to provide point-of-care support and informa-
tion on primary care COPD management in the USA led to 
a significant reduction in exacerbations and improvement 
in COPD control medication prescription.111 In the UK, 
a national clinical audit for hospitalized exacerbations of 
COPD found improvements in process indicators when 
continuous audit was combined with quality improvement 
support and, in particular, financial incentives.17 These 
studies contain elements that are similar to planned com-
ponents of CONQUEST and suggest that providing infor-
mation and guidance at the point-of-care can lead to closer 
adherence to clinical guidelines. However, overall, results 
have been mixed and a reduction in mortality has not yet 
been shown. This may have been because of the short-term 
nature of some of these initiatives, their tendency to focus 
on severe disease, and failure to fully integrate into health-
care systems. Patient-reported outcomes and information 
were also under-utilized and quality improvement meth-
odologies were of mixed quality and heterogenous.116
CONQUEST overcomes many of these limitations. It 
promotes more proactive and hence earlier diagnosis, since 
undiagnosed COPD patients have an increased risk of 
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exacerbations and pneumonia, compared to those without 
COPD. Targeting undiagnosed patients at risk (≥40 years 
old and ever smokers) including the presence of previous 
respiratory symptoms and exacerbations, should increase 
diagnostic yield, improve disease outcomes, reduce health-
care resource utilization, and help to inform national/inter-
national guidelines and policies to support earlier 
prevention and treatment intervention in COPD.
Limitations to CONQUEST QS implementation 
include the fact that global and local quality improvement 
protocols for implementation may need to be modified 
depending on the country adopting these standards. Any 
modifications required would be based on the various 
nuances of healthcare policy and differences in national 
recommendations and guidelines, which may impact 
a global delivery of the program. Moreover, variability in 
availability of technology and/or access to electronic 
record systems for patient identification (especially in 
lower income countries) may also impact ability to imple-
ment CONQUEST QS. As the QS will be implemented, 
and their impact assessed in the UK and the USA initially, 
we acknowledge that these countries may not be represen-
tative of the situation elsewhere. Challenges encountered 
in each country may be different (eg, data protection 
issues, completeness of EMRs and differentiation between 
primary and secondary care), particularly with respect to 
socio-economic burden of lower income countries, and 
also differences in access to, and availability of, pharma-
cological treatments. On the strengths side of the equation, 
CONQUEST QS have been informed by 11 key thought 
leaders from a variety of backgrounds, including represen-
tation from primary and specialist care, academics, patient 
advocacy groups and the pharmaceutical industry. The QS 
will help to address potential disconnects between local/ 
national and global approaches, are consensus and evi-
dence-based, will be reviewed and updated as new evi-
dence emerges or whenever necessary, and will be 
embedded into primary and secondary care processes.
Next steps for CONQUEST include the translation of 
these QS into Quality Improvement Program operational 
protocols, which describe the core components of the 
program required to implement CONQUEST in 
a healthcare system or practice. The USA and the UK 
have been identified for the initial delivery of the inter-
vention, as these countries have a well-documented burden 
of COPD, existing quality improvement programs, and 
EMR integration into healthcare systems. An Opportunity 
Analysis using retrospective analysis of EMRs to compare 
the QS with current practice in each of these countries will 
be undertaken to describe the opportunities for manage-
ment optimization. The impact of the CONQUEST inter-
vention on COPD outcomes (eg, rate of exacerbations and 
major adverse cardiac or respiratory events, COPD con-
trol, lung function, systemic corticosteroid burden) will be 
evaluated by a cluster randomized controlled trial (CRT) in 
each country (PREVAIL study).
Conclusions
The CONQUEST QS are the first step on an international 
journey to improve care of the COPD patient in primary and 
secondary care. They aim to transform the patient pathway, 
by identifying patients with modifiable high risk of future 
exacerbations, optimizing management and follow-up of 
patients with diagnosed COPD to reduce symptoms, exacer-
bations, co-morbidity, and mortality. Moving forward 
CONQUEST will advocate for appropriate and early treat-
ments to slow disease progression, optimize patient out-
comes including improved HRQoL, encourage follow-up 
with patients and HCPs utilizing shared decision-making to 
lock in behavior change, and generate transformational evi-
dence to measure treatment success.
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